ANEB (Anebulo Pharmaceuticals) Moat Score: 2/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANEB Anebulo Pharmaceuticals Inc ANEB
35 GF Score
Price $0.33
! 1 Warning Sign
View Full Analysis

What is Anebulo Pharmaceuticals Moat Score?

Anebulo Pharmaceuticals ANEB 35 Moat Score is 2 as of Aug. 01, 2026. GuruFocus rates ANEB with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,394 Biotechnology companies, Anebulo Pharmaceuticals ranks better than 58.32% on this metric.

Anebulo Pharmaceuticals has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Anebulo Pharmaceuticals has No Moat: Anebulo Pharmaceuticals has a very weak moat with some intellectual property in pharmaceuticals. However, it lacks market leadership, brand strength, and significant customer switching costs. The biotech industry is highly competitive and risky.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Anebulo Pharmaceuticals might have No Moat - Very weak/transient advantages.

Anebulo Pharmaceuticals  (OTCPK:ANEB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Anebulo Pharmaceuticals Moat Score Related Terms

ANEB vs PHIO, COCP, CALC: Moat Score Comparison

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anebulo Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Moat Score falls into.


ANEB
35GF Score
Anebulo Pharmaceuticals Inc ANEB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Anebulo Pharmaceuticals (ANEB) has a Moat Score of 2 as of Aug. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Anebulo Pharmaceuticals ranks #581 out of 1394 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Anebulo Pharmaceuticals' Moat Score too high?
Anebulo Pharmaceuticals' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Anebulo Pharmaceuticals' value of 2 is 0% at this industry median. Based on the distribution chart, Anebulo Pharmaceuticals ranks #581 out of 1394 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Anebulo Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Anebulo Pharmaceuticals' Moat Score compare to PHIO and COCP?
According to the Biotechnology industry distribution chart, Anebulo Pharmaceuticals ranks #581 out of 1394 companies for Moat Score. This puts Anebulo Pharmaceuticals in the upper half of its industry. The industry median Moat Score is 2.00. Anebulo Pharmaceuticals' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anebulo Pharmaceuticals's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anebulo Pharmaceuticals's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anebulo Pharmaceuticals stock overvalued right now?
Anebulo Pharmaceuticals (ANEB) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Anebulo Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Anebulo Pharmaceuticals (ANEB), the current Moat Score is 2 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anebulo Pharmaceuticals Business Description

Address 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score

Get the complete analysis for ANEB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price